Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kartesian
Frederick, Maryland, United States
- Ownership
- Private
- Employees
- ~66
- Development stage
- Other
01
Overview
Cartesian Therapeutics is a clinical-stage biotechnology company developing autologous mRNA CAR-T and other mRNA-engineered cell therapies for autoimmune diseases. Its lead program, Descartes-08, an autologous anti-BCMA mRNA CAR-T, has completed Phase 2 studies in generalized myasthenia gravis with positive safety and efficacy signals and is in Phase 2b for generalized myasthenia gravis and Phase 2 for systemic lupus erythematosus, with rare pediatric disease designation for juvenile dermatomyositis.[1][2][3][4][5]
- Therapeutic areas
- RheumatologyOncologyImmunologyNeurology
- Modalities
- Cell therapymRNA-based drugsCAR-T cell therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Kartesian.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kartesian.